W.H. Wilson Tang

Dr. W.H. Wilson Tang

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2017 in Circulation Research
Verified
Journal Article
Open access
PDF file
WTW.H. Wilson Tang
W.H. Wilson Tang
TKTakeshi Kitai
Takeshi Kitai
SHStanley L. Hazen
Stanley L. Hazen
Significant interest in recent years has focused on gut microbiota–host interaction because accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies such as atherosclerosis, hypertension, heart failure, chronic kidney disease, obesity, and type 2 diabetes mellitus. In addition to alterations in gut microbiota composition, the metabolic potential of gut microbiota has been identified as a contributing factor in the development of diseases. Recent studies revealed that gut microbiota can elicit a variety of effects on the host. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites, that can impact host physiology. Microbiota interact with the host through many pathways, including the trimethylamine/trimethylamine N -oxide pathway, short-chain fatty acids pathway, and primary and secondary bile acids pathways. In addition to these metabolism-dependent pathways, metabolism-independent processes are suggested to also potentially contribute to cardiovascular disease pathogenesis. For example, heart failure–associated splanchnic circulation congestion, bowel wall edema, and impaired intestinal barrier function are thought to result in bacterial translocation, the presence of bacterial products in the systemic circulation and heightened inflammatory state. These are thought to also contribute to further progression of heart failure and atherosclerosis. The purpose of the current review is to highlight the complex interplay between microbiota, their metabolites, and the development and progression of cardiovascular diseases. We will also discuss the roles of gut microbiota in normal physiology and the potential of modulating intestinal microbial inhabitants as novel therapeutic targets.

1 February 2009 in JACC
Verified
Journal Article
Closed access
WMWilfried Mullens
Wilfried Mullens
ZAZuheir Abrahams
Zuheir Abrahams
GFGary S. Francis
Gary S. Francis
GSGeorge Sokos
George Sokos
DTDavid O. Taylor
David O. Taylor
WTW.H. Wilson Tang
W.H. Wilson Tang

30 January 2015 in Circulation Research
Verified
Journal Article
Closed access
PDF file
WTW.H. Wilson Tang
W.H. Wilson Tang
ZWZeneng Wang
Zeneng Wang
DKDavid J. Kennedy
David J. Kennedy
YWYuping Wu
Yuping Wu
JBJennifer A. Buffa
Jennifer A. Buffa
SHStanley L. Hazen
Stanley L. Hazen
Rationale:: Trimethylamine- N -oxide (TMAO), a gut microbial-dependent metabolite of dietary choline, phosphatidylcholine (lecithin), and l -carnitine, is elevated in chronic kidney diseases (CKD) and associated with coronary artery disease pathogenesis. Objective:: To both investigate the clinical prognostic value of TMAO in subjects with versus without CKD, and test the hypothesis that TMAO plays a direct contributory role in the development and progression of renal dysfunction. Methods and Results:: We first examined the relationship between fasting plasma TMAO and all-cause mortality over 5-year follow-up in 521 stable subjects with CKD (estimated glomerular filtration rate, <60 mL/min per 1.73 m 2 ). Median TMAO level among CKD subjects was 7.9 μmol/L (interquartile range, 5.2–12.4 μmol/L), which was markedly higher ( P <0.001) than in non-CKD subjects (n=3166). Within CKD subjects, higher (fourth versus first quartile) plasma TMAO level was associated with a 2.8-fold increased mortality risk. After adjustments for traditional risk factors, high-sensitivity C-reactive protein, estimated glomerular filtration rate, elevated TMAO levels remained predictive of 5-year mortality risk (hazard ratio, 1.93; 95% confidence interval, 1.13–3.29; P <0.05). TMAO provided significant incremental prognostic value (net reclassification index, 17.26%; P <0.001 and differences in area under receiver operator characteristic curve, 63.26% versus 65.95%; P =0.036). Among non-CKD subjects, elevated TMAO levels portend poorer prognosis within cohorts of high and low cystatin C. In animal models, elevated dietary choline or TMAO directly led to progressive renal tubulointerstitial fibrosis and dysfunction. Conclusions:: Plasma TMAO levels are both elevated in patients with CKD and portend poorer long-term survival. Chronic dietary exposures that increase TMAO directly contributes to progressive renal fibrosis and dysfunction in animal models.

8 November 2018 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
WTW.H. Wilson Tang
W.H. Wilson Tang
DLDaniel Y. Li
Daniel Y. Li
SHStanley L. Hazen
Stanley L. Hazen

1 November 2014 in JACC
Verified
Journal Article
Closed access
WTW.H. Wilson Tang
W.H. Wilson Tang
ZWZeneng Wang
Zeneng Wang
YFYiying Fan
Yiying Fan
BLBruce Levison
Bruce Levison
JHJennie E. Hazen
Jennie E. Hazen
SHStanley L. Hazen
Stanley L. Hazen

1 April 2019 in JACC
Verified
Journal Article
Closed access
WTW.H. Wilson Tang
W.H. Wilson Tang
FBFredrik Bäckhed
Fredrik Bäckhed
ULUlf Landmesser
Ulf Landmesser
SHStanley L. Hazen
Stanley L. Hazen